Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WuXi PharmaTech and Open Monoclonal Technology (OMT) have entered into an agreement to use OMT's OmniRat to develop therapeutic antibody candidates for commercialization by WuXi's global customers.
Subscribe to our email newsletter
The OmniRat technology generates fully human antibodies with specificity, affinity and manufacturability, according to WuXi.
The technology eradicates time-consuming humanization of traditional mouse-derived antibodies and the need to optimise lead candidates using phage display technology.
WuXi PharmaTech chief operating officer and chief financial officer Edward Hu said providing discovery, development and manufacturing services for novel therapeutic antibodies represents a new global business initiative for WuXi.
”We are investing heavily in building our capabilities and capacity in biologics services, which we expect to be a key driver of revenue growth for our company in the coming years," Hu added.
OMT founder and CEO Roland Buelow said the collaboration with WuXi further advances OMT’s efforts to deploy its human antibody platform globally.
”Under the collaboration, OMT can leverage WuXi’s expertise and capacity to create novel therapeutic candidates for its biopharmaceutical customers and apply OMT’s technology to an ever-broadening base of drug candidates," Buelow added.